Page 4 - நெதர்லாந்து புற்றுநோய் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article A novel protein-based multitarget fecal immunochemical test (mFIT) for colorectal cancer (CRC) screening was superior to conventional FIT in detecting advanced neoplasia, particularly advanced adenomas, Dutch researchers found. If performed on patients every 2 years, mFIT would reduce CRC incidence and death by 12% and 8%, respectively, assuming a 73% adherence rate, compared with conventional FIT screening, reported Meike de Wit, PhD, of The Netherlands Cancer Institute in Amsterdam, and colleagues. These rates would increase to 17% and 11%, respectively, with perfect adherence, they noted in Furthermore, the authors determined that mFIT, when applied to a validated screening model, was cost effective up to at least $84 per test.

United statesNoord hollandMike bassettJason dominitzHepatology program of the veterans health administrationNetherlands cancer instituteNational gastroenterologyMeike de witHepatology programVeterans health administrationIntern medஒன்றுபட்டது மாநிலங்களில்நூற்த் ஹாலண்ட்மைக் பாசெட்நெதர்லாந்து புற்றுநோய் நிறுவனம்இன்டர்ன் மேட்